Clinical Trial Update: A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CAELYX (pegylated liposomal doxorubicin) to topotecan hydrochloride in recurrent epithelial ovarian cancer after failure of first-line p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)
• Topotecan hydrochloride (topotecan hydrochloride)

Snippet

Sponsor: Xian-Janssen Pharmaceutical Ltd. | Conditions: Epithelial Ovarian Cancer | Phase 3 | Status: TERMINATED | Results posted: 2015-12-23